loading page

Maintenance of neutralizing SARS-CoV-2 antibodies over five months in convalescent SARS-CoV-2 afflicted patients.
  • +10
  • Sissy Sonnleitner,
  • Martina Prelog,
  • Bainca Jansen,
  • Chantal Rodgarkia-Dara,
  • Sarah Gietl,
  • Carmen Schönegger,
  • Stephan Koblmüller,
  • Christian Sturmbauer,
  • Wilfried Posch,
  • Giovanni Almanzar,
  • Hanna Jury,
  • Norbert Nowotny,
  • Gernot Walder
Sissy Sonnleitner
Dr. Gernot Walder GmbH
Author Profile
Martina Prelog
University Hospital Wurzburg
Author Profile
Bainca Jansen
Dr. Gernot Walder GmbH
Author Profile
Chantal Rodgarkia-Dara
THP Medical products
Author Profile
Sarah Gietl
Dr. Gernot Walder GmbH
Author Profile
Carmen Schönegger
Dr. Gernot Walder GmbH
Author Profile
Stephan Koblmüller
University of Graz
Author Profile
Christian Sturmbauer
University of Graz
Author Profile
Wilfried Posch
Medical University of Innsbruck
Author Profile
Giovanni Almanzar
University Hospital Wurzburg
Author Profile
Hanna Jury
University Hospital Wurzburg
Author Profile
Norbert Nowotny
Mohammed Bin Rashid University of Medicine and Health Sciences
Author Profile
Gernot Walder
Dr. Gernot Walder GmbH
Author Profile

Abstract

Level and duration of protective immunity against SARS-CoV-2 after primary infection is of crucial importance for preventive approaches. In order to provide evidence for the longevity of specific antibodies, we investigated the generation and maintenance of neutralizing antibodies of convalescent SARS-CoV-2-afflicted patients over a five month period post primary infection using an immunofluorescence assay, a commercial chemiluminescent immunoassay and an in-house enzyme-linked plaque-reduction neutralization assay. We present the successful application of an improved version of the plaque-reduction neutralization assay, which can be analyzed optometrically, significantly simplifying the interpretation of the results. Based on the results of the plaque-reduction neutralization assay, neutralizing antibodies were maintained in 85.3% of convalescent individuals without significant decay over five months. Furthermore, a positive correlation between severity of infection and neutralizing titer was shown. In conclusion, SARS-CoV-2-afflicted individuals have been proven to be able to establish and maintain neutralizing antibodies over a five months’ period after primary infection which allows to hope for long-lasting presumably protective humoral immunity after wild-type infection or even after vaccination.

Peer review status:IN REVISION

08 Dec 2020Submitted to Transboundary and Emerging Diseases
09 Dec 2020Assigned to Editor
09 Dec 2020Submission Checks Completed
11 Dec 2020Reviewer(s) Assigned
04 Feb 2021Review(s) Completed, Editorial Evaluation Pending
09 Feb 2021Editorial Decision: Revise Major